Agile therapeutics reports fourth quarter & full year 2023 financial results and provides corporate update

Full year 2023 net revenue increased 80% from 2022 while opex decreased 33% twirla demand and factory sales up 121% and 114% respectively in 2023 vs 2022 company completes pay-off of debt facility in first quarter 2024 twirla demand expected to rebound in first quarter 2024 from decreased demand in fourth quarter 2023 management to host conference call today, thursday, march 28, 2024 at 8:30 a.m. et princeton, n.j.
AGRX Ratings Summary
AGRX Quant Ranking